

Investment Objective

To achieve consistent and above average capital appreciation over the medium to long-term by investing in companies with market capitalization of not more than RM750 million at the time of acquisition.

Investor Profile

The fund is suitable for investors who are willing to accept higher level of risk in order to obtain higher growth of their capital and have a medium to long term investment horizon.

Fund Manager

UOB Asset Management (Malaysia)

Fund Details

Unit NAV RM3.8643

Fund Size RM81.8 million

Inception Date 1 April 2005


Management Fee 1.50% per annum

Top 10 Holdings

Dufu Technology	9.1%
D&O Green Technologies	8.1%
Frontken	7.4%
Pentamaster	6.8%
Duopharma Biotech	6.1%
Formosa Prosonic	5.3%
Pharmaniaga	4.7%
Thong Guan	4.3%
Johore Tin	3.3%
PIE Industrial	3.0%

Data as at 30 June 2021

Cumulative Performance Since Inception as at 30 June 2021



Performance Table as at 30 June 2021


	1 month	3 months	6 months	YTD	1 year	3 years	5 years	Since inception
Fund	-1.2%	-0.4%	4.7%	4.7%	39.7%	69.9%	75.6%	713.5%
Benchmark	-3.0%	-3.9%	-5.1%	-5.1%	5.7%	-6.7%	-3.2%	90.2%

• Benchmark: FTSE Bursa Malaysia Emas Index

• Source: Bloomberg & Gibraltar BSN Life Bhd

Past performance is not indicative of future performance and the performance of the fund is not guaranteed.

Portfolio Composition as at 30 June 2021



Source: UOBAM



Manager's Comment

For June 2021, the Fund's NAV/unit decreased by 1.2%, outperformed the FBM EMAS which decreased by 3.0% mainly due to the Fund's overweight position in the technology sector.

It was a mixed month for equities as the US Fed turned hawkish in the June FOMC meeting. Developed markets saw renewed interest for growth stocks which more than offset the weakness in value names. Meanwhile, emerging markets underperformed due to a stronger US Dollar and high Covid-19 cases, which dampened recovery in some major emerging markets.

In Malaysia, the FBM KLCI Index declined by 3.2% to close at 1,533 points as the country extended the Full Movement Control Order (FMCO) with new daily Covid-19 cases remaining above the 5,000 mark. During the month, the government announced the National Recovery Plan (NRP) which outlines the metrics to determine the timeline for exit from the FMCO. Separately, the government unveiled its 10th stimulus package, PEMULIH, with a total value of RM150bn, bringing the country's cumulative stimulus package tally to RM530bn.

Brent crude oil futures gained 8.4% to close at US\$75/bbl as US crude stock fell for six straight weeks. CPO price slumped by 8.2% weighed down by a weaker vegetable oil complex and expectations of a production recovery in key producing regions.

Moving forward, the uneven recovery in Malaysia continues with the extended lockdown. With vaccination rates increasing rapidly as more vaccine supplies are available, we expect the market to look beyond the current lockdown and to focus on improved earnings prospects with reopening. We would adopt a barbell strategy and target to have a balanced exposure in both growth and value/reopening sectors. For growth exposure, we prefer the technology and industrial sector. As for value/reopening, we focus on consumer and commodities.

Disclaimer

This report is for information only and is purely a product summary. Please refer to the product fact sheet available at www.gibraltarbns.com for further details. This report shall not be reproduced, copied, circulated or forwarded either in part or otherwise to any persons howsoever without the prior written consent of Gibraltar BSN Life Berhad.

The opinions and information contained herein are based on the latest available data which is believed to be reliable. It is not to be construed as an offer, invitation or solicitation to buy or sell any securities or financial instruments covered by this report. Gibraltar BSN Life Berhad does not warrant the accuracy of anything stated herein in any manner whatsoever and no reliance upon such statement by anyone shall give rise to any claim whatsoever against Gibraltar BSN Life Berhad and/or its associated persons. Gibraltar BSN Life Berhad and/or its associated persons may from time to time have an interest in the securities or financial instruments mentioned by this report. Past Performance of the Funds mentioned in the Report is not an indication of its future performance. Investors/policy holders should rely on their own evaluation to assess the merits and risks of the investment. In considering to invest in an investment-linked fund, investors/policy holders who are in doubt on the action to be taken should consult a professional adviser. Investors/Policy holders have to take note that investments can fluctuate in value and values may fall as well as rise and an investor/policy holder may not get back the amount invested.